Kymanox Relationships

Kymanox News

By Nathan Blazei, MEng, ASQ CQA
Senior Manager, Quality + Compliance

As an engineering and compliance service provider in the life science industry, we are tasked with building and maintaining positive relationships every day. Positive relationships take time, commitment, honesty, trust, and openness to build and maintain. They are mutually beneficial, unassuming, and resilient. When relationships are ignored, taken advantage of, de-prioritized, or otherwise suffer, it can have a devastating effect on a business and ultimately the patient communities we all aim to serve.

This may sound intuitive, however there are few industries that have the complexity of relationships that we experience in the life sciences. We work in a field that has many interconnected parts that are sometimes at conflict with one another. The expectations are so incredibly high, and the margin for error is razor thin. Life science companies have to provide mutual benefit to our employees, our investors, our shareholders, our patient communities, our medical professionals, our insurance providers, our business partners, and our governments at the same time. And the goals of each of these stakeholders are not always aligned, which makes the job at hand all the more challenging.
We have seen a prime example of the challenge to building and maintaining positive relationships recently with the EpiPen from Mylan, which is used for emergency treatment of severe allergic reactions. As a parent of a child with a severe peanut allergy, I am obligated to have EpiPens on hand at all times. My son has them at school, we have them at home, and we take them with us everywhere we go. And right now there are few, if any, reliable alternatives to consider. As the EpiPen’s price continues to rise, Mylan runs the risk of not being able to get EpiPens into the hands of those in our community who need them for survival.

Mylan is facing intense public scrutiny because of what could in many ways be traced back to poor relationship management. While the debate continues and the government mulls its options for how to address this situation, one is left to wonder if Mylan lost sight of the goals of some of their stakeholders in favor of those of others. Right or wrong, they are now under the microscope of an entire nation. Where they go from here will have a profound impact on the many relationships they have built over the years. And some will likely never recover.

At Kymanox, we put tremendous value on building and maintaining positive relationships with our employees, our clients, our business partners, our community, our government, and the various patient populations we serve.

We understand the challenge of working in this industry and we know the expectations are always sky high. We embrace that challenge, and we look forward to building and maintaining a positive relationship with all of you in the years to come in order to continue advancing modern medicine together.